420 with CNW — Massachusetts Marijuana Prohibitionists Survive Lawsuit, Petition Remains

A legal effort to overturn Massachusetts’ adult-use cannabis framework cleared a significant hurdle after the state’s highest court upheld the petition process, keeping it on track for a possible appearance on the November 2026 ballot.

The Massachusetts Supreme Judicial Court determined on June 12 that state AG Joy Campbell acted within her authority when she certified, in September 2025, a ballot proposal that seeks to dismantle the state’s recreational marijuana system, a market valued at about $1.6 billion and approved by voters in 2016 with 54% support.

The campaign, led by the Coalition for a Healthy Massachusetts, cleared the first signature-gathering stage after submitting 74,574 verified signatures in December. Organizers must now collect an additional 12,429 signatures from registered voters by next month. The requirement came after state lawmakers chose not to advance the proposal during the legislative review process.

Four voters tried to stop it, claiming multiple subjects and an unfair summary lacking mention of social equity trust fund elimination and alleged uncompensated taking.

The challenge asserted that the petition combined unrelated policy areas and that the official summary failed to fairly describe impacts, particularly the removal of programs supporting equity funding, which they argued could constitute an unlawful taking.

The court disagreed, with Justice Elizabeth N. Dewar writing that the certification met constitutional requirements and that the summary adequately reflected the measure’s scope, sending the matter back to a lower court for final judgment.

It would repeal chapters 94G and 64N, ending rules governing retail sales, cultivation, possession framework, and taxation of nonmedical cannabis, while preserving the legal right for adults to grow up to six plants at home.

It would leave medical marijuana laws intact and would not reinstate criminal penalties for adults 21 and older holding up to one ounce of marijuana or five grams of concentrate, though smaller violations would still face civil fines.

It would introduce mandatory drug education and community service requirements for younger offenders and create an expedited route for existing recreational businesses to transition into the medical cannabis sector.

The plaintiffs argued that the medical and recreational frameworks are separate policy areas and that removing requirements such as host community agreements and adding youth penalties placed unrelated elements into a single proposal.

The court concluded that all provisions share a unified objective of tightening controls on recreational cannabis rather than advancing unrelated policy goals.

The justices also found the attorney general’s summary sufficiently clear, noting it conveyed the central effect of the measure while pointing out that voters receive additional explanatory materials prepared by Secretary of the Commonwealth William Galvin.

Recent polling indicated the proposal faces significant resistance, with about 63% of respondents opposing repeal and roughly 20% expressing support.

The developments in Massachusetts will be closely watched by the marijuana movement, including enterprises like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), because the ballot measure could trigger similar steps to be taken in other legal marijuana markets in years to come.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Chicago Class-Action Lawsuit Alleges Deceptive Advertising of Medical Marijuana Products

A newly filed federal class-action lawsuit is raising questions about how cannabis products are promoted in the U.S., with plaintiffs arguing that some of the industry’s largest companies have misled consumers about both benefits and potential health risks.

The case, submitted in federal court in May, targets three Chicago-based cannabis operators: Verano Holdings, Cresco Labs, and Green Thumb Industries. Spanning over 300 pages, the complaint alleges the companies presented cannabis products as effective for a wide range of medical and psychological conditions while failing to adequately communicate possible adverse effects.

According to the lawsuit, the businesses promoted cannabis as a remedy for issues such as chronic pain, anxiety, sleep disorders, and certain autoimmune conditions, despite the fact that cannabis has not received approval from the FDA for those treatments.

The filing describes what it calls a coordinated industry effort to market products containing high levels of THC, the primary psychoactive component in cannabis. Attorneys representing the plaintiffs argue that marketing campaigns have emphasized therapeutic claims while minimizing concerns about potential harm.

The lawsuit references multiple scientific studies examining the effects of cannabis use. Among them is a 2017 NASEM report that identified evidence linking marijuana consumption to an increased likelihood of schizophrenia and other psychotic disorders, particularly among frequent users.

Patrick Kenneally, an attorney with Burke Law Group representing the plaintiffs, said clearer warnings are needed so consumers can make informed purchasing decisions. He argued that some users experiencing mental health or physical problems may not recognize a possible relationship between those issues and their cannabis consumption.

Kenneally also compared the current debate surrounding marijuana to public discussions about tobacco decades ago, before widespread awareness campaigns and health warnings became common. He said greater public education, whether through labels, packaging inserts, or in-store notices, is necessary to ensure consumers understand potential risks.

The lawsuit also alleges financial injury, claiming customers may have paid premium prices or bought products they otherwise would have avoided if more complete information had been available.

Verano Holdings responded in a statement, noting that it is part of a broader legal campaign against multi-state marijuana operators and noting that similar claims have previously been dismissed by courts. The company stated that it complies with state regulations governing testing, labeling, and consumer warnings.

Verano also pointed to recent federal actions and long-standing state medical marijuana programs as evidence of official recognition of cannabis’s medical uses. The company said it intends to contest the allegations in court.

Kenneally, who noted he was not involved in the lawsuits cited by Verano, said the legal battle could take several years to resolve.

This case is likely to be followed by companies like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) and other licensed marijuana companies that make and sell medical marijuana products in the U.S. as its outcome could impact the trajectory of the industry.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — New York Cannabis Social Equity Entrepreneurs Stuck As State Support Underwhelms

When New York legalized recreational marijuana in 2021, it framed the move as a step toward restorative justice, promising an industry that would benefit communities most harmed by prohibition.

A central piece of that plan was the Conditional Adult-Use Retail Dispensary (CAURD) program, designed to give retail licenses to individuals with prior cannabis-related convictions. The idea was that those most impacted by decades of enforcement would be first in line to take part in the legal market.

Applicants followed state requirements, completed training, submitted paperwork, and waited through delays while investing personal savings to prepare for opening.

Later, the state launched a $200 million Social Equity Cannabis Investment Fund through the Dormitory Authority of the State of New York (DASNY) to provide low-interest financing for leases and construction.

In practice, buildouts were routed through state-approved vendors, and costs often escalated beyond expectations, leaving operators with limited control over key decisions.

Financing structures involved private partners, including Chicago Atlantic, a real estate investment trust active in cannabis lending, which helped shape loan terms tied to these projects.

As a result, many license holders entered operations carrying multi-million-dollar debt burdens in a market that was shifting faster than projections anticipated.

One example is Stoops, a cannabis retail shop in Manhattan’s Flatiron District built as a neighborhood-focused store emphasizing education, compliance, and community engagement. The business model included local hiring, tax compliance, and strict adherence to regulatory rules.

Despite these efforts, operators have faced mounting pressure from falling marijuana prices and ongoing competition from an unlicensed market that continues to operate across the state. Additionally, some CAURD operators tied to DASNY and Chicago Atlantic financing face repayment terms that no longer match market reality.

What was meant to be a path to ownership and repair has, for many, become a financial strain that threatens the survival of the entrepreneurs the program was designed to support.

These concerns contributed to the formation of CAURD Inc., a member-led organization composed of early CAURD license holders seeking coordinated advocacy. The group is calling for restructuring or partial relief of state-backed loans, greater transparency in how construction costs and interest rates were determined, increased flexibility in vendor selection, and improved access to working capital to stabilize legal operators.

Advocates argue that while regulatory oversight remains important, financial burdens tied to the program’s design should not fall disproportionately on small businesses that entered the market under the promise of economic justice and restorative opportunity.

Operating in the state-legal marijuana industry has always been challenging, and even well-established firms like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) are grappling with operational challenges linked to the regulatory systems in the jurisdictions where they have operations.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Medical Marijuana Could Expand as Feds Reschedule the Drug

A recent federal decision to reclassify medical cannabis is reshaping the outlook for licensed operators, prompting renewed attention from businesses and regulators across the country.

The change, introduced under an order signed by Acting Attorney General Todd Blanche, moves state-approved medical cannabis to Schedule III of the CSA. That adjustment carries significant financial implications, particularly when it comes to taxation.

Beginning in the first quarter of 2026, companies operating in the medical marijuana space will be allowed to deduct ordinary business expenses. This marks a sharp departure from previous restrictions that fell under Section 280E of the Internal Revenue Code, which has long prevented cannabis businesses from claiming such deductions.

According to data from analytics firm Headset, the average dispensary could save around $268,000 annually under the new classification. For many businesses that have struggled to remain profitable, those savings could shift the balance, turning losses into gains.

Recreational marijuana operators, however, remain subject to those rules for now, creating a split in how the industry is taxed. These operators are awaiting the outcome of a fast-tracked administrative review scheduled to begin June 29 and wrap up by mid-July.

The process will determine whether they might also benefit from relief tied to Section 280E. Until then, operators and regulators are weighing their options.

Some states are already moving ahead. In California, officials have introduced a simplified system that allows cannabis businesses to modify their license type without waiting for renewal. The Department of Cannabis Control said the change is intended to speed up approvals and reduce administrative hurdles. Businesses can now shift to a medical designation or add one alongside an existing adult-use license with fewer requirements.

The policy shift comes as California’s once-dominant medical marijuana market has sharply declined. Sales that exceeded $2.5 billion in 2017 dropped to below $185 million by 2025. Industry observers point to high taxes, registration costs, and limited product access as factors that have driven patients elsewhere. Many have either turned to unregulated sellers or opted to purchase through adult-use channels despite having medical needs.

The new federal classification may encourage businesses to refocus on serving medical patients, given the financial advantages now tied to that segment. It could also prompt regulators to expand access to medical licenses, particularly in states where those permits are currently concentrated among large, well-funded operators.

In New Jersey, where recreational sales launched in 2022 through existing medical providers, regulators may consider allowing more businesses to enter the medical market. Industry consultants say discussions are already underway, though officials are still evaluating how best to respond to the evolving federal framework.

Other states may take broader approaches. Some could consider redefining their entire cannabis market as medical in order to extend tax benefits to all licensed operators. Washington, D.C. offers a notable example. Although voters approved recreational marijuana in 2014, federal restrictions have prevented the city from establishing a traditional retail system for recreational sales.

As a workaround, leaders created a system that allows adults over 21 to register as medical patients without a physician’s recommendation, enabling them to purchase cannabis legally through licensed dispensaries.

The model could gain traction elsewhere if states look for ways to align with federal policy while supporting local businesses.

Meanwhile, debate continues at the national level. Critics, including some lawmakers, argue that more research is needed on the health effects of cannabis before further regulatory changes are made.

The evolving regulatory climate at the federal level is going to be closely watched by medical cannabis firms like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF).

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Marijuana Sales Record Major Spike on 4/20

Cannabis retailers across the U.S. recorded a notable surge in sales on April 20 (4/20) this year, with particularly strong gains in states that have recently approved legal use.

Data released by online ordering company Jane Technologies shows that total sales on April 20 climbed by 46.9% compared to the same date last year. The number of transactions also rose sharply, increasing by 46.6%. The figures reflect activity from stores that were operating in both 2025 and 2026, a method the company used to avoid overstating growth due to newly opened locations.

Socrates Rosenfeld, co-founder and chief executive of Jane Technologies, said the yearly spike offers insight into broader trends shaping the market. He noted that demand continues to expand as more states embrace legalization. He added that businesses focusing on improving the customer experience are gaining a competitive edge.

Retailers saw a significant jump in daily traffic as well, with transactions on April 20 rising 73% compared to the previous day.

At the state level, performance varied. Illinois posted the strongest results, leading all markets with a 44.5% increase in sales compared to last year. California, the nation’s largest cannabis market, recorded a 25.8% gain. Maryland followed with a 31.5% increase. In contrast, some established markets experienced slight declines. Nevada saw sales dip by 2.7%, New Jersey by 1.1%, and Colorado by 7.1%.

Minnesota reported a dramatic 150% rise in sales, though analysts caution that the figure is influenced by the state’s recent shift to recreational marijuana, which began late last year.

Product preferences remained largely consistent with previous trends. Traditional marijuana flower accounted for the largest share of purchases, making up 43% of total sales. Vape products followed at 27%, while edibles represented 14%. Pre-rolled products captured 10%, and concentrates and extracts made up the remaining 6%.

Despite the positive results tied to April 20, the broader market picture is more complex. In California, for example, total annual cannabis sales reached $3.9 billion last year, down from $4.2 billion in 2024. This suggests that while peak events drive strong short-term gains, the industry continues to face challenges.

Rosenfeld added that the sector is evolving rather than slowing down. He pointed to increasing competition and changing consumer expectations as signs of a maturing market. According to him, companies that focus on long-term strategies are likely to benefit as the industry develops further.

Meanwhile, data from marijuana analytics firm Lit Alerts indicates that 4/20 does not rank among the top ten sales days in several states, including Missouri, New York, Ohio, New Jersey, Maryland, and Massachusetts.

That particular insight is a matter that cannabis firms like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) will analyze in order to establish any lessons that can guide their future strategies.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — How Federal Reclassification Could Reshape Marijuana Taxes

Last December, President Trump signed Executive Order 14067, titled “Increasing Medical Marijuana and Cannabidiol Research.” The directive calls for marijuana to be reclassified from Schedule 1 to 3 under the Controlled Substances Act (CSA), a move that could reshape the financial landscape for cannabis businesses.

The proposal is not yet in effect. It must pass through a federal rulemaking process and may face legal challenges along the way. Even so, industry participants are already evaluating what a lower tax burden could mean for their operations, long-term planning, and expansion strategies.

A key issue is Section 280E of the Internal Revenue Code, which currently blocks companies involved in controlled substances from claiming standard business deductions.

Under current rules, cannabis companies cannot deduct routine expenses like rent, payroll, marketing, or legal services. This restriction significantly raises their effective tax rates. Businesses can, however, subtract the cost of goods sold when calculating income.

These costs include items such as raw materials, packaging, and certain labor tied directly to production. Since these are treated as adjustments rather than deductions, they fall outside the limits of 280E.

This distinction has encouraged companies to allocate as many expenses as possible to inventory under Section 263A. However, this strategy has limits. Larger firms, especially those with annual revenues above $25 million, face restrictions that reduce the benefits of this approach.

The combined effect of these tax rules has placed heavy financial pressure on cannabis operators, particularly retailers. If cannabis is moved to Schedule III, those limitations would no longer apply. Businesses would be able to deduct ordinary expenses like other industries, improving profitability and cash flow.

The timing of any tax relief remains unclear. The order does not set a firm deadline, and it is uncertain whether changes would apply retroactively. Most companies are expected to continue filing taxes under existing rules until new guidance is issued.

In the meantime, operators should review their financial structures and consider how different business entities could affect future tax outcomes. Choices such as operating as a C corporation, LLC, or S corporation may carry more weight under a revised system.

Despite the potential tax benefits, other challenges are unlikely to disappear quickly. Recreational cannabis would still lack federal approval, and state regulations would remain in place. Access to banking services, major investment markets, and payment systems is expected to improve only gradually. Legal risks tied to financial regulations may ease in practice, though formal rules may not change significantly.

For larger marijuana firms like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), the rulemaking process couldn’t have come at a better time because the industry has for so long been hamstrung by the existing regulations, and any reforms would be a welcome development.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Colorado Governor Enacts Bill Allowing MMJ Use in Hospitals

Colorado Governor Jared Polis has approved new legislation allowing patients with terminal illnesses to access medical cannabis while receiving care in hospitals and similar facilities. While supporting the bill, Polis raised concerns that revisions may have moved it away from its original intent.

Speaking during the bill signing, Polis highlighted the state’s history of recognizing the therapeutic benefits of cannabis. He noted that many patients nearing the end of life depend on cannabis to ease symptoms such as chronic pain, nausea, anxiety, and loss of appetite. For some, he said, it can mean remaining conscious and connected with loved ones rather than being heavily medicated in their last days.

However, changes introduced by lawmakers before the bill reached the governor’s desk altered a key provision. Rather than requiring healthcare facilities to allow medical cannabis use, the final version gives hospitals and care centers the choice to opt in. Polis said this adjustment could limit the law’s real-world impact, adding that some institutions may decide not to adopt the policy at all.

Despite those concerns, the governor said he chose to move forward with the bill, describing it as a step in the right direction. He suggested that even a limited policy could encourage healthcare institutions to reconsider their approach to patient autonomy and comfort. At the same time, he emphasized that further action will likely be necessary to ensure broader protections for individuals with terminal illnesses.

Advocacy groups and supporters argue that making participation voluntary weakens the intent of the reform and could lead to inconsistent access across the state. Jim Bartell, whose late son inspired similar legislation known as Ryan’s Law in California and other states, urged lawmakers to restore stronger language. He added that families facing end-of-life decisions need clear, reliable access, not a system that varies by facility.

Under the newly signed measure, healthcare facilities may establish their own rules regarding how medical cannabis is handled, including guidelines for administration and storage. The state’s public health and environment department is barred from tying compliance with the policy to licensing or certification requirements. Facilities may also suspend participation if they face potential federal enforcement risks.

Additional provisions clarify that hospitals are not obligated to supply or manage cannabis directly and offer legal protections for those that permit its use. Meanwhile, a separate proposal aimed at increasing taxes on alcohol and cannabis to fund mental health services failed to advance in a House committee last month.

Marijuana firms like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) focusing on medical marijuana will be pleased that Colorado is moving in the right direction by enacting reforms that permit patients to use their MMJ products even when they are in hospital.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Washington State Lawmakers Send Bill Allowing MMJ Use in Hospitals to Governor

Lawmakers in Washington State have approved a proposal that would allow patients with terminal illnesses to use medical marijuana in certain healthcare facilities, including hospices, hospitals, and nursing homes. The measure now awaits action from Governor Bob Ferguson.

The bill, introduced by Representative Shelley Kloba, cleared the state Senate with a 46 to 2 vote and the House by a margin of 89 to 6.

If the governor signs the measure, hospices, hospitals, and nursing homes across the state would be required to allow qualified patients with terminal conditions to use medical marijuana at those locations beginning January next year. The policy would apply only under defined conditions intended to maintain safety within healthcare environments.

According to the legislation, the use of cannabis for medical purposes may help improve comfort and overall well-being for people facing terminal conditions. Lawmakers said the proposal aims to support dignity and relief for patients during their final stage of life while still protecting safety standards in medical environments.

Under the proposal, patients would not receive cannabis directly from healthcare facilities. Instead, individuals or their designated caregivers would be responsible for obtaining the product, bringing it to the facility, and assisting with its use. The cannabis would need to be kept in a locked container whenever it is not being used.

Smoking and vaping would not be allowed inside the facilities. Patients would have to rely on other forms, such as edibles, oils, or similar alternatives. Cannabis will not be shared among patients, visitors, or staff. The policy would also not apply to individuals being treated in hospital emergency departments.

Facilities would be required to confirm that patients have proper authorization for medical cannabis use. Staff members would also have to document that use in the patient’s medical record. Each facility would need to establish a formal policy outlining how medical cannabis may be used on-site.

The legislation also provides flexibility if federal agencies intervene. Hospitals or care centers could temporarily halt cannabis use if federal authorities, such as the Justice Department, take enforcement action or issue guidance prohibiting the practice in healthcare facilities.

Lawmakers made several adjustments to the bill during the legislative process. One amendment exempts nursing homes run by residential rehabilitation centers from the requirement. Other changes clarify that the rules apply only to patients formally admitted to a hospital and confirm that patients and caregivers must handle transportation of the cannabis product themselves.

Similar policies already exist in several other states, including California. Often referred to as Ryan’s Law, it is named after Ryan Bartell, a cancer patient whose family pushed for expanded access to medical cannabis during end-of-life care.

Bartell’s father, Jim Bartell, had sought permission for his son to receive cannabis treatment while hospitalized. At first, the request was denied. Eventually, the family located a facility that allowed it. According to Bartell, the treatment helped his son remain alert and communicate more comfortably with loved ones during his final days.

Such regulatory reforms premised on compassionate grounds are a welcome development to major players in the medical marijuana industry, such as Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) that focus on making marijuana products formulated to help in the management of various symptoms.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Florida Supreme Court Considers Appeal to Put Marijuana on State Ballot

Efforts to legalize recreational cannabis in Florida remain active as the state’s highest court weighs whether to take up a key appeal that could determine if voters see the issue on a future ballot.

The Florida Supreme Court is reviewing a request from the Smart and Safe Florida campaign after roughly 71,000 petition signatures were thrown out. If the justices agree to hear the case and ultimately side with the campaign, the proposed constitutional amendment could move forward to the ballot in November.

The group contends that the disputed petitions were improperly invalidated and should be included in the final tally required for ballot access. State officials previously excluded signatures tied to voters listed as inactive, people residing outside Florida, and forms that did not contain the complete wording of the proposed amendment. Campaign organizers say they submitted more than 1.4 million signatures overall, far surpassing the 880,062 required to qualify for placement before voters.

The latest proposal is a revised version of a 2024 amendment that fell short of passage. Although it earned a majority of support at the polls, it did not reach the 60% approval required to amend the state constitution.

In response to concerns raised during that campaign, the updated measure includes new restrictions. It would bar vaping or smoking cannabis in public areas and direct lawmakers to establish rules governing when and where cannabis could be consumed outside private property.

Opposition, however, remains strong. Governor Ron DeSantis, who actively campaigned against the earlier proposal, has argued that the amendment conflicts with the state constitution. Business organizations have also criticized the initiative, contending that outsiders are attempting to use the state’s citizen initiative process for their own gain.

The campaign is also facing legal scrutiny, with state AG Ashley Moody’s office recently launching dozens of criminal investigations tied to alleged fraud in the petition-gathering process.

Subpoenas were issued seeking records from the campaigners as well as from subcontractors involved in collecting signatures. Campaign representatives have denied wrongdoing and said they are cooperating with authorities.

Despite the legal and political obstacles, backers of the initiative say they remain confident. They point to changes made after the 2024 vote and continued support from segments of the marijuana industry as signs that the measure has a viable path forward.

For now, the next move rests with the Florida Supreme Court. Its decision on whether to hear the appeal, and how it rules if the case proceeds, will shape whether voters get another opportunity to weigh in on recreational marijuana in the coming election cycle.

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), a company that has heavily invested in efforts to legalize adult-use marijuana, will be closely following what the Supreme Court in the state decides on this matter placed before it.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Why the US Should Avoid Making Canada’s Medical Marijuana Mistake

President Donald Trump’s executive order issued on December 18 signaled a shift in US medical cannabis policy, opening new paths for research and fueling a wave of mergers and acquisitions across the sector. However, one essential issue remains unresolved: how will patients receive medical marijuana in a way that resembles standard healthcare?

Canada confronted this same problem years ago, and its experience offers a cautionary tale.

In 2016, Canadian authorities broadened access to medical marijuana nationwide. While many viewed the decision as progressive, the chosen framework at the time left significant gaps. Healthcare professionals, particularly pharmacists, were largely excluded from the system. Cannabis could be authorized by physicians, but it was not prescribed in the traditional sense, nor dispensed through pharmacies.

That structure became even more problematic after Canada legalized recreational marijuana in 2018. Many observers expected that adult-use legalization would finally bring medical marijuana into mainstream healthcare settings. Instead, the divide deepened. Doctors continued to issue general authorization documents rather than prescriptions, often without specifying dosage, formulation, or method of use. Pharmacists remained on the sidelines, unable to guide patients directly at the point of care.

Meanwhile, recreational marijuana became widely available through retail stores and online platforms that were often more accessible than medical channels. For many patients, especially those dealing with neurological conditions, chronic pain, or nausea, the recreational market offered speed, convenience, and lower costs. Clinical oversight became a secondary concern.

That shift carried risks. Cannabis can interact with other medications and requires careful guidance on dosing and timing—the kind of support that pharmacists offer. However, that support was largely missing.

Within regulatory limits, some organizations tried to fill the gap. Call centers staffed by licensed pharmacists offered education on proper use, side effects, and potential interactions. Efforts were made to steer patients toward safer formulations and to apply basic pharmaceutical standards to product review.

While patients valued that support, the model was not financially viable. Counseling could not be sustained when purchases flowed through nonmedical channels. Ultimately, the initiative ended not because demand was lacking, but because the system made true medical delivery unworkable.

As U.S. cannabis policy continues to evolve, the country faces a similar crossroads. The central question is no longer about access alone. It is about delivery. Canada’s experience highlights the risks of prioritizing access while sidelining healthcare professionals. If marijuana is to be treated as a medication in the U.S., pharmacists will need to play a central role in providing it.

For medical marijuana companies like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), a model that improves service to patients would be of great help in ensuring patients can access professional help as they use medical marijuana to manage their symptoms.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com